• The coordinating human development and culture minister, Puan Maharani handed an award to PT Dexa Medica for its active role in "Innovating the National Drugs Development" on Wednesday, February 11, 2015, at the Food and Drugs Agency (BPOM) Building, Jakarta. The Event was witnessed by the Health Minister, Prof. Dr. dr. Nila Farid Moeloek, Sp.M(K), and the Head of BPOM, Dr. Ir. Roy Alexander Sparringa, M.App.Sc.

    Dexa Medica's contribution was in the innovation of the national drugs development,namely; 1. As the pioneer of generic drugs with logo (OGB) - producing OGB with the pharmacy high technology since 1991, 2. As the pioneer for natural resources based drug development in the form of Bioactive Fraction, 3. Drugs clinical trial development.

    President Director PT Dexa Medica, Ir. Ferry Soetikno, MSc., MBA explained his commitment in supporting the government program by producing OGB since 1991. "We inaugurated a new pharmaceutical plant facility equipped with high technology a few years ago to increase production capacity and to ensure that the quality of each product comply with the good manufacturing practices (GMP) standard," said Mr. Soetikno after receiving the award from BPOM.

    He also said that while the Dexa Laboratories of Biomolecular Sciences (DLBS) PT Dexa Medica production facility in Cikarang, West Java, is able to produce active herbal ingredients in the form of Bioactive Fraction, "We are the first pharmaceuticals company in Indonesia to produce herbal Bioactive Fraction,"

    It was Minister of Health of the Republic of Indonesia, Ibu dr. Nafsiah Mboi, SpA, M.P.H. who handed over the production permit for Natural Ingredients Extraction Industry (IEBA) and inaugurated the Bioactive Fraction DLBS Dexa Medica production facillities on Tuesday, August 20, 2013.

    The medicinal drugs produced by DLBS and marketed by PT Dexa Medica are; Inlacin (oral anti-diabetic drugs), Redacid (gastric disorders, gastroprotector), Vitafem Free Me (premenstrual syndrome), and Phalecarps (breast cancer).

    For more information on DLBS, click here to read the following article in Bahasa Indonesia. Corporate Communications